Myotrophin "Potentially Approvable" Letter Requests More Efficacy Data
A "potentially approvable" letter for Cephalon/Chiron's Myotrophin issued May 12 indicates that the recombinant growth factor protein for the treatment of amyotrophic lateral sclerosis will receive approval only if an ongoing Japanese Phase III trial shows efficacy.
You may also be interested in...
The US FDA is set for two high-profile advisory committee meetings on potential ALS treatments before the end of 2022. Whatever the outcome, they will fit a pattern: when it comes to ALS treatments, there is very little about the regulatory process that feels routine.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials